Pharmalex Sweden (PLX) is a consultancy and research company specialising in health economic evaluations and generation of real-life evidence-data for pharmaceuticals and medical technologies. The company was founded in 2003 and since then has completed a large number of successful reimbursement and market access projects in the Nordic countries and conducted a comprehensive list of studies that have been published in peer-reviewed scientific journals.

​

The staff members have backgrounds in the pharmaceutical industry, the pharmacy profession and academic research institutes. Strong emphasis is placed upon professional excellence, and every member of the staff holds a PhD degree within health economics, pharmacology, epidemiology or medicinal science. PLX offers an array of scientific grade services in prospective and retrospective health economics and outcomes research, for example: strategic advice on health economics, health economic assessment through modelling, designing and analysing health-economic studies alongside clinical trials, designing and conducting studies for generation of real-life evidence; including both prospective and retrospective studies, and preparation of health economics dossiers for applications to reimbursement benefits boards.

​

PLX has also conducted a large number of cost-of-illness studies and cost-effectiveness analyses in our function as a consultancy company.

​

Role in project:

​

PLX will undertake the role of providing health economic expertise and will work in close collaboration with other partners. PLX will:

1. Identify the health care resource use to be collected;

2. Elicit unit costs relevant for the respective countries, and;

3. Perform health economic analyses based on the study results.

Contributing staff: ​

​